Effects of Clofibrate and of an Estrogen-Progestin Combination on Fasting Biliary Lipids and Cholic Acid Kinetics in Man

Pertsemlidis, Demetrius; D, Panveliwalla; Ahrens, E. H.

doi:10.1016/s0016-5085(74)80045-4

Cited by 171 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 In the present study Rowachol increased total lipid output and total lipid concentration of duodenal content (0.67 g/l versus 087 g/l; p<005). This observation is in line with results of 35 Bell et a139 who show that Rowachol (100 mg tid) given to gall stone patients three months before cholecystectomy increased biliary lipid concentration significantly. Thus, the increase in biliary lipid concentration produced by Rowachol might contribute to the litholytic properties of this mixture of plant monoterpenes.…”

Section: Mechanism Of Cholesterol Gall Stone Dissolution By Rowacholsupporting

confidence: 91%

Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers.

Leiß¹,

Bergmann²

1985

Gut

View full text Add to dashboard Cite

SUMMARY The effect of Rowachol (200 mg tid), an essential oil preparation, on biliary lipid secretion and serum lipids was measured in six healthy male volunteers before and after four weeks of treatment. Biliary cholesterol and phospholipid secretion increased significantly from 113±36 (SD) ,umol/h to 155±52 ,umol/h (p<0.05) and from 409±145 ,umol/h to 587±185 ,umol/h (p0-05 and >0.10). This marked increase in biliary lipid secretion was not followed by a change in molar composition of biliary lipids and lithogenicity of bile. Serum cholesterol and triglycerides declined from 4.9 mmol/l to 4-1 mmol/l (p<0O05) and from 1-2 mmol/l to 0.9 mmol/l (p<0O05) respectively. The ratio of high-density-lipoprotein cholesterol to total cholesterol increased from 0.22 to 0-31 (p<005). Although it has been shown previously that Rowachol could dissolve cholesterol gall stones the present results indicate that Rowachol alone has only weak litholytic properties, at least in normal volunteers, but might have several advantages when combined with chenodeoxycholic or ursodeoxycholic acid.

show abstract

Section: Mechanism Of Cholesterol Gall Stone Dissolution By Rowacholsupporting

confidence: 91%

Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers.

Leiß¹,

Bergmann²

1985

Gut

View full text Add to dashboard Cite

show abstract

“…Clofi brate is used extensively in the treatment of hyperlipidemia but it causes bile to become oversaturated with cholesterol (76). Such patients have an increased frequency of gallstones (77).…”

Section: Cdca and Blood Lipidsmentioning

confidence: 99%

The Medical Treatment of Gallstones

Bouchier¹

1980

Annu. Rev. Med.

View full text Add to dashboard Cite

“…During such therapy, a fall in serum triglycerides has been observed whereas serum cholesterol is unaffected (Bell, Lewis, Petrie & Dowling, 1973;Hoffman, Hofmann & Thistle, 1974;Iser, Dowling, Mok & Bell, 1975). As hypertriglyceridaemia per se appears to be linked to an increased risk of gallstone development (Einarsson, Hellström & Kallner, 1975) and as triglyceride-lowering agents such as clofibrate increase biliary cholesterol saturation (Pertsemlides, Panveliwalla & Ahrens, 1974) and gallstone incidence (Coronary Drug Project, 1975;Cooper, Geizerova & Oliver, 1975), chenodeoxycholic acid may be useful in treatment of hypertri glyceridaemia. Previous studies have reported a significant reduction (Miller & Nestel, 1974) as well as no changes (Schlierf, Stiehl, Heuch, Lang, Oster & Schellenberg, 1976) in serum triglycerides in hypertriglyceridaemic patients treated with chenodeoxycholic acid, whereas no information on changes in biliary lipids in these patients is presently available.…”

Section: Introductionmentioning

confidence: 99%

Effect of Chenodeoxycholic Acid on Serum and Biliary Lipids in Patients with Hyperlipoproteinaemia

1978

View full text Add to dashboard Cite

1. In order to study the effects of chenodeoxycholic acid on serum and biliary lipids in hyperlipoproteinaemia, chenodeoxycholic acid was administered to seven type IIa, eight type IIb and eight type IV patients in a daily dose of 750 mg (1.9 mmol) for 3 months. 2. The serum concentrations of cholesterol and triglycerides were determined at 4-week intervals: cholesterol remained unchanged whereas triglycerides decreased 15--20%. 3. In 17 patients, biliary lipids were studied. The proportion of chenodeoxycholic acid in the bile increased to about 70%; lithocholic acid and ursodeoxycholic acid increased significantly. 4. Bile saturation with cholesterol decreased and correlated negatively with the proportion of chenodeoxycholic acid in biliary bile acids but positively with serum triglycerides. 5. It is concluded that chenodeoxycholic acid treatment in hyperlipoproteinaemia is associated with parallel fall in serum triglycerides and biliary cholesterol and thus may prove to be a useful adjunct in hypolipidaemic treatment.

show abstract

Effects of Clofibrate and of an Estrogen-Progestin Combination on Fasting Biliary Lipids and Cholic Acid Kinetics in Man

Cited by 171 publications

References 21 publications

Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers.

Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers.

The Medical Treatment of Gallstones

Effect of Chenodeoxycholic Acid on Serum and Biliary Lipids in Patients with Hyperlipoproteinaemia

Contact Info

Product

Resources

About